The model suggests that negative KRAS findings are believable when the maximum of APC and TP53 frequencies is at least 8% (corresponding posterior probability of false negative <5%). Validation ...
Sotorasib is more cost-effective in treating patients with KRAS G12C non–small cell lung cancer (NSCLC) compared with ...
Dr. Marwan G. Fakih explains that KRAS mutations, found in 45% of patients with colorectal cancer, include the rare KRAS G12C mutation, leading to Lumakras approval. According to the National Cancer ...
Hosted on MSN
Landscape of KRAS mutations and targeted therapies in colorectal cancer mapped in new study
A team of researchers from the Germans Trias i Pujol Research Institute (IGTP) and Institut Català d'Oncologia (ICO) has studied alterations in the KRAS gene in colorectal cancer by combining genomic ...
In Brazil, the early detection of genetic alterations in lung cancer through liquid biopsies could be a valuable tool for ...
KRAS-driven cancers have long been considered undruggable due to the protein’s uncommon shape. Because KRAS is smooth and round, it was difficult to find a targeted drug that could wedge in and block ...
A common mutation in the KRAS gene is associated with improved overall survival in pancreatic ductal adenocarcinoma (PDAC) compared with other variants, in part because the mutation appears to lead to ...
Margaret and her husband, David, were able to travel to Mexico because a clinical trial drug called zoldonrasib successfully controlled her lung cancer, which had returned after treatment. Dr. Kathryn ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback